Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 156,243	$ 141,666
Accounts receivable	54,369	96,043
Inventories	18,582	15,161
Deferred tax assets, net	1,264	1,264
Income tax receivable, net	6,502	0
Prepaid expenses and other current assets	11,199	9,213
Total current assets	248,159	263,347
Property, plant and equipment, net	248,504	241,764
In process research and development	41,800	41,800
Goodwill	5,502	5,502
Deferred tax assets, net	11,087	11,087
Other assets	562	730
Total assets	555,614	564,230
Current liabilities:
Accounts payable	25,711	31,297
Accrued expenses and other current liabilities	1,067	1,603
Accrued compensation	15,481	22,726
Long-term indebtedness, current portion	4,470	4,470
Deferred revenue	2,049	1,811
Total current liabilities	48,778	61,907
Long-term indebtedness, net of current portion	56,069	58,304
Other liabilities	1,685	1,891
Total liabilities	106,532	122,102
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 36,589,921 shares issued and 36,186,763 shares outstanding at June 30, 2013; 36,272,550 shares issued and 35,869,392 shares outstanding at December 31, 2012	36	36
Additional paid-in capital	236,099	230,964
Treasury stock, at cost, 403,158 common shares at June 30, 2013 and December 31, 2012	(5,906)	(5,906)
Accumulated other comprehensive loss	(3,513)	(4,129)
Retained earnings	222,814	220,393
Total Emergent BioSolutions Inc. stockholders' equity	449,530	441,358
Noncontrolling interest in subsidiaries	(448)	770
Total stockholders' equity	449,082	442,128
Total liabilities and stockholders' equity	$ 555,614	$ 564,230